Cellectis Romainvil (CMVLF) 35.6000 $CMVLF Cellectis

New Post Public Reply Private Reply Replies (0) Message Board

Jul 11, 2015 at 9:37 AM

Cellectis Romainvil (CMVLF) 35.6000 $CMVLF

Cellectis Reaches Milestone in Servier Collaboration
Business Wire - Wed Jul 08, 4:00PM CDT
Regulatory News:
CLLS: 35.72 (+1.27)

PharmaSphere: Emerging Biotechnologies - Gene Therapy Market Analysis of the 20 Leading Biotech Companies
M2 - Thu Jul 02, 5:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rfrgdp/pharmasphere) has announced the addition of the "PharmaSphere: Emerging Biotechnologies - Gene Therapy Market Analysis" company profile to their offering. "PharmaSphere: Emerging Biotechnologies - Gene Therapy Market Analysis" report is an essential source of information and analysis on the gene therapy field. Using detailed company data, deal analysis, corporate strategy, and market trends analysis, The publisher provides an in-depth analysis of the current and future growth drivers of the gene therapy market. The report discusses the key factors shaping and driving the gene therapy business, and provides insights on the competitive landscape and emerging strategies expected to significantly influence the market positions of companies currently involved in the development and commercialization of gene therapies. Key Questions Answered - What are the drivers of the gene therapy field? - Who are the leading companies involved in the development of gene therapies? - What are the major trends in gene therapy clinical trials? - What specific therapeutic areas and indications are receiving the most clinical research? - What progress has been made in terms of viral vector technology and gene delivery? - What specific business development activities are taking place in terms of partnerships or mergers and acquisitions (M&As)? - Has investor confidence been restored in the gene therapy field? Scope - This report provides market developments across the gene therapy field, including clinical trials, deals, and pipeline investments - Investment examined on both the industry and financial communities - Broad discussion on the science behind gene therapies, viral vectors, and gene delivery - Clinical trials activity examined across phase of development, therapy area, and indication. - This report offers a deep dive into the synergies behind partnering and acquisition activity - Deals activity examined across geography, entity type, company, financial advisor, phase of development, therapy area, indication, and mechanism of action - Pipeline profiles of 20 leading biotech companies developing gene therapies Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Gene Therapy Overview 4 Market Developments 5 Clinical Trials 6 Company Analysis 7 Deals Landscape 8 Strategic Outlook 9 Appendix Companies Mentioned - Advantagene - ALS Therapy Development Institute - Amarna Therapeutics - American Gene Technologies - AnGes MG - Applied Genetic Technologies International - Asklepios BioPharmaceutical - Avalanche Biotechnologies - Benitec BioPharma - Bluebird bio - Celladon - Cellectis - CFR Pharmaceuticals - Chiesi Farmaceutici - Dimension Therapeutics - GeneCure Biotechnologies - Genethon - GenSight Biologics - InoCard - Oxford BioMedica - Proximagen - ReGenX Biosciences - Sangamo BioSciences - Spark Therapeutics - Tacere Therapeutics - TransgeneTransposagen - UniQure - Voyager Therapeutics For more information visit http://www.researchandmarkets.com/research/rf...armasphere
ONCE: 60.80 (+1.43), SGMO: 9.86 (-0.02), AAVL: 16.25 (+0.62)

Biotech Investors Should Read Bibliographies Of Chief Scientific Officers
Intrepid Investor - at Seeking Alpha - Tue Jun 30, 11:42AM CDT

BLUE: 159.03 (+0.60), BIIB: 388.23 (-11.06), TBIO: 1.37 (-0.02), SGMO: 9.86 (-0.02), SRNE: 17.09 (+0.39), CELG: 118.84 (+1.97), VICL: 0.70 (unch), GILD: 113.74 (+0.38), SGEN: 47.09 (+0.57), AEZS: 0.24 (+0.01), REGN: 526.01 (+16.98)

Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2015 Featuring 90+ Companies
M2 - Thu Jun 25, 6:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5gpct9/type_1_diabetes) has announced the addition of the "Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Type 1 Diabetes (Juvenile Diabetes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - 30 of the 93 Companies Featured - 4SC AG - ActogeniX NV - Adocia - AiCuris GmbH & Co. KG - Amarantus Bioscience Holdings, Inc. - Ambrx, Inc. - American Gene Technologies International Inc. - AntriaBio, Inc. - Argos Therapeutics, Inc. - Artery Therapeutics, Inc. - AstraZeneca PLC - Axxam SpA - Bayhill Therapeutics, Inc. - Beta-Cell NV - Biocon Limited - Biodel Inc. - Biogenomics Limited - BioLineRx, Ltd. - BioTherapeutics Inc. - Boehringer Ingelheim GmbH - Carlina Technologies SAS - Cellectis S.A. - Compugen Ltd. - Cortendo AB - CTI BioPharma Corp. - Daewoong Pharmaceutical Co., Ltd. - Diabetology Limited - DiaMedica Inc. - Diasome Pharmaceuticals, Inc. - Dompe Farmaceutici S.p.A For more information visit http://www.researchandmarkets.com/research/5g...1_diabetes
AMBX: (), CTIC: 1.91 (+0.03), BIOD: 1.02 (+0.04), ARGS: 6.45 (+0.69), AZN: 66.45 (+1.90), CGEN: 6.63 (+0.06)

Cellectis Announces Promising Study on Next Generation Engineered Allogeneic CAR T-cells
Business Wire - Wed Jun 10, 4:02PM CDT
Regulatory News:
CLLS: 35.72 (+1.27)

S&W Seed Company and Calyxt, Inc. Announce Alfalfa Seed Collaboration
Business Wire - Tue Jun 09, 4:36PM CDT
Regulatory News:
SANW: 4.65 (+0.07)

Cellectis Reports First Quarter 2015 Financial Results
Business Wire - Tue Jun 09, 4:30PM CDT
Regulatory News:
CLLS: 35.72 (+1.27)

Cellectis to Present Data on its Allogeneic CAR T-Cell Immunotherapy Programs at the European Hematology Association Annual Meeting
Business Wire - Thu Jun 04, 5:30PM CDT
Regulatory News:
CLLS: 35.72 (+1.27)

Weill Cornell Medical College and Cellectis Announce Research Alliance Advancing Drug Discovery and the Translation of Novel Immunotherapies in Leukemia
Business Wire - Tue Jun 02, 4:00PM CDT
Regulatory News:
CLLS: 35.72 (+1.27)

Cellectis SA Combined General Shareholders' Meeting of May 18, 2015
Business Wire - Tue May 19, 5:15PM CDT
Regulatory News:
CLLS: 35.72 (+1.27)

Cellectis to Present Data on Genome Engineering for Adoptive Immunotherapy at the American Society of Clinical Oncology Annual Meeting
Business Wire - Wed May 13, 5:00PM CDT
Regulatory News:
CLLS: 35.72 (+1.27)

Cellectis S.A. to Present Data on its Allogeneic CAR T Cell Programs at American Society of Gene & Cell Therapy Annual Meeting
Business Wire - Thu May 07, 5:00PM CDT
Regulatory News:
CLLS: 35.72 (+1.27)

Cellectis Plant Sciences Becomes Calyxt
Business Wire - Mon May 04, 5:05PM CDT
Cellectis plant sciences, Inc., a Minnesota-based Company focusing on developing healthier food products, announced today that it has changed its corporate name to Calyxt, Inc. The company will use this new name as of today.

Cellectis S.A. Announces Calyxt is New Name for Its Plant Sciences Subsidiary
Business Wire - Mon May 04, 5:00PM CDT
Regulatory News:
CLLS: 35.72 (+1.27)

Cellectis Plant Sciences, Inc. Locks Early CRISPR Intellectual Property Uses in Plants
Business Wire - Wed Apr 15, 5:02PM CDT
Regulatory News:

Cellectis Plant Sciences, Inc. Publishes a Study Demonstrating Reduced Acrylamide in Fried Potatoes
Business Wire - Tue Apr 14, 5:14PM CDT
Regulatory News:

Cellectis Announces Presentations at Upcoming Conferences
Business Wire - Thu Apr 09, 5:24PM CDT
Regulatory News:
CLLS: 35.72 (+1.27)

Cellectis Opens Labs and Offices in Manhattan, New York
Business Wire - Wed Apr 08, 5:17PM CDT
Regulatory News:
CLLS: 35.72 (+1.27)

Citi Appointed Depositary Bank for Cellectis' ADR Programme
Business Wire - Wed Apr 08, 6:44AM CDT
Citi, acting through Citibank N.A., has been appointed by Cellectis S.A. ("Cellectis"

, a gene-editing company, as depositary bank for their Level 3 American Depositary Receipt (ADR) programme listed on Nasdaq Global Market, which trades under symbol "CLLS". Each ordinary share is equivalent to 1 ADR. Cellectis' ordinary shares are listed on Alternext Paris and trade under symbol "ALCLS".
C: 54.56 (+0.85)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

FDA Greenlights Halozyme's Cancer Treatment Breakthrough

FDA's Seal of Approval: A Game Changer Well, folks, here's a twist in the story of cancer treatment with FDA giving a nod to RYBREVANT FASPRO. Johnson & Johnson's latest offering, fueled by Halozyme's groundbreaking ENHANZE technology, just snagged accelerated approval. We're not just talking any old treatment here; it's a dual-targeted therapy for head and neck cancer...

Investor Bidding on Off-Market Homes Surges 35% Higher

Investor Frenzy in Off-Market Real Estate Looking at the real estate puzzle today, one might spot an unexpected surge in enthusiasm for off-market residential properties. We've got iFinder Offers, a real estate platform that's made it its business to connect the dots between homeowners and a gaggle of over 325 hungry investors. And according to their magic spreadsheets,...

CalExitNow Push for CA GOP Ban & Sovereignty Talks

California's Political Pot Stirs In the wild world of politics, California stands as a fiery beacon yet again. This time, CalExitNow, a fiery group championing California's self-determination, is taking aim at the state’s Republican Party. Reminds me of a stock under pressure—hesitate at your peril as the winds of change sweep through. Disqualification Petition: A...

INOVIO's $75M Offering: A Tough Medicine for Investors

A Shot in the Arm or a Sore Spot? INOVIO Pharmaceuticals is diving headfirst into the capital markets with a $75 million public offering, and let me tell you, the road ahead isn't paved with gold, yet. They've set out to raise funds by pricing 58,747,235 shares at $1.05 a pop, which might have you scratching your head if you're holding INO shares already. Breaking Down...

AiNET Prevails in Breach of Contract Jury Verdict

AiNET's Legal Triumph Shakes Up the IT Sector Well, talk about a courtroom drama. Greenberg Traurig just snagged a big win for AiNET over in Prince George's County, Maryland, and it's a classic reminder that due diligence isn't just a nice-to-have—it's a must. AiNET found itself in the center of a breach of contract brawl with Tech Finance Co., and guess what? The jury...

Lilly's Digital Healthcare Push with Hims & Hers

Revolutionizing Access: Pharmaceuticals Meet Telehealth In an era where digital disruption is shaking every sector, Eli Lilly (NYSE:LLY) isn't sitting idle. They've just forged a partnership with Hims & Hers (NYSE:HIMS), one that's diving headfirst into the telehealth revolution. We're talking a slick merger of pharmaceuticals and digital platforms—offering FDA-approved...

Everest Group Faces Class Action: Key Investor Moves

Everest Group's Legal Spiral: What's Happening? Folks, when a company feels like it's caught in an endless storm, investors better hold on tight. That's the situation Everest Group, Ltd. finds itself in, with an 11.4% stock dive that’s got investors reeling. Securities fraud allegations are rocking Everest like a hurricane, and The Law Offices of Frank R. Cruz have put...

Brian Long Exits Atlantic Bridge for US Tech Fund

Well, here we go again with another shake-up in the tech investment world. Brian Long, a name that's been whispered around more than a few boardroom tables, is dropping out of Atlantic Bridge to start his own gig across the pond in the United States. If you're tracking numbers, Atlantic Bridge is juggling a healthy €1.4bn in assets—no small potatoes. So, let's dig...

LaserAway Opens 241st Clinic, Marks 20-Year Milestone

LaserAway's New Chapter in Paramus Out of the glitz of Los Angeles and into the hustle of Paramus, LaserAway's latest clinic isn't just a ribbon-cutting ceremony—it's a milestone in the aesthetic dermatology space. Boasting its 241st location, LaserAway is marking twenty years of relentless expansion without ever closing a single clinic. Now that's a track record that'd...

TELUS Targets Debt Reduction Amid Telecom Transformation

Adjusting Strategy Amid Financial Challenges The market's a tough beast, and TELUS seems to be wrestling with it, showing both grit and foresight in its latest quarterly update. Third quarter 2026 has TELUS down on revenues with a notable net loss but don't count them out yet. Their Transformation Strategy is a gamble worth watching. Where the Numbers Stand Here's the...